Biotech | October 04, 2022
Construction is now underway with the facility scheduled to be operational by 2025
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
Subscribe To Our Newsletter & Stay Updated
